Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with or without ociperlimab in previously treated recurrent or metastatic cervical cancer
2020-004657-77Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and ociperlimab in Cervical Cancer (CC) (2 arms), sponsored by BeiGene. Primary endpoint: Objective response rate by independent review committee. Started Mar 2021; status: completed.
02
Drugs
tislelizumabociperlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2020-004657-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004657-77.